Checkpoint Therapeutics Stock Filter Stocks by Fundamentals
| CKPT Stock | USD 4.31 0.08 1.82% |
Checkpoint Therapeutics fundamentals help investors to digest information that contributes to Checkpoint Therapeutics' financial success or failures. It also enables traders to predict the movement of Checkpoint Stock. The fundamental analysis module provides a way to measure Checkpoint Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Checkpoint Therapeutics stock.
Checkpoint | Shares Owned by Insiders |
Checkpoint Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Checkpoint Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Checkpoint Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Checkpoint Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Checkpoint Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Checkpoint Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Checkpoint Therapeutics' value.| Shares | Legacy Wealth Asset Management, Llc | 2024-09-30 | 85 K | Envestnet Asset Management Inc | 2024-09-30 | 83.6 K | Hb Wealth Management, Llc | 2024-09-30 | 78 K | Walleye Trading Advisors, Llc | 2024-09-30 | 65.9 K | Marshall Wace Asset Management Ltd | 2024-09-30 | 62.7 K | Northern Trust Corp | 2024-09-30 | 62.3 K | Royal Bank Of Canada | 2024-09-30 | 60.9 K | Park Avenue Securities Llc | 2024-09-30 | 59.9 K | Rsm Us Wealth Management Llc | 2024-09-30 | 59.3 K | Armistice Capital, Llc | 2024-09-30 | 3.9 M | Vanguard Group Inc | 2024-09-30 | 1.4 M |
Checkpoint Fundamentals
| Return On Equity | -12.2 | ||||
| Return On Asset | -3.17 | ||||
| Operating Margin | (162.76) % | ||||
| Current Valuation | 209.67 M | ||||
| Shares Outstanding | 48.13 M | ||||
| Shares Owned By Insiders | 15.51 % | ||||
| Shares Owned By Institutions | 13.91 % | ||||
| Number Of Shares Shorted | 6.03 M | ||||
| Price To Earning | (7.60) X | ||||
| Price To Book | 8.56 X | ||||
| Price To Sales | 2,709 X | ||||
| Revenue | 103 K | ||||
| Gross Profit | (48.19 M) | ||||
| EBITDA | (52.15 M) | ||||
| Net Income | (51.85 M) | ||||
| Cash And Equivalents | 30.89 M | ||||
| Cash Per Share | 0.33 X | ||||
| Total Debt | 18.43 M | ||||
| Debt To Equity | 0.1 % | ||||
| Current Ratio | 1.30 X | ||||
| Book Value Per Share | (0.47) X | ||||
| Cash Flow From Operations | (47.59 M) | ||||
| Short Ratio | 5.70 X | ||||
| Earnings Per Share | (1.83) X | ||||
| Target Price | 17.0 | ||||
| Number Of Employees | 23 | ||||
| Beta | 1.24 | ||||
| Market Capitalization | 211.3 M | ||||
| Total Asset | 5.38 M | ||||
| Retained Earnings | (314.33 M) | ||||
| Working Capital | (13.05 M) | ||||
| Current Asset | 46.85 M | ||||
| Current Liabilities | 2.89 M | ||||
| Net Asset | 5.38 M |
About Checkpoint Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Checkpoint Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Checkpoint Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Checkpoint Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Checkpoint Stock Analysis
When running Checkpoint Therapeutics' price analysis, check to measure Checkpoint Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Checkpoint Therapeutics is operating at the current time. Most of Checkpoint Therapeutics' value examination focuses on studying past and present price action to predict the probability of Checkpoint Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Checkpoint Therapeutics' price. Additionally, you may evaluate how the addition of Checkpoint Therapeutics to your portfolios can decrease your overall portfolio volatility.